Compare Amphastar Pharmaceuticals Inc (AMPH) vs Zillow Group Inc Class C (Z) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Zillow Group (Z) trades at $32.19, down 3.74% on the day. The stock shows mixed technical signals with a neutral overall stance. Fundamentally, the company reported revenue of $2.58 billion in 2025 with a net income of $23 million, marking a return to profitability. However, a high P/E ratio of 128.76 indicates significant growth expectations are priced in. Recent news is dominated by multiple securities class action lawsuits filed against the company.

The outlook is clouded by legal risks, though analyst consensus remains optimistic with a $63 price target. The primary opportunity lies in the company's strong revenue growth and high gross margins, but investors must weigh this against the overhang from litigation and the stock's demanding valuation.